Lipocine Inc. (NASDAQ:LPCN – Get Free Report)’s share price passed above its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $5.00 and traded as high as $5.23. Lipocine shares last traded at $4.89, with a volume of 10,352 shares trading hands.
Wall Street Analyst Weigh In
A number of analysts have recently commented on the stock. Alliance Global Partners assumed coverage on shares of Lipocine in a research note on Tuesday, September 24th. They set a “buy” rating and a $10.00 target price for the company. StockNews.com downgraded shares of Lipocine from a “buy” rating to a “hold” rating in a research note on Thursday, November 7th.
View Our Latest Stock Analysis on LPCN
Lipocine Price Performance
Lipocine (NASDAQ:LPCN – Get Free Report) last announced its quarterly earnings results on Thursday, November 7th. The specialty pharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter. On average, sell-side analysts expect that Lipocine Inc. will post -0.78 EPS for the current fiscal year.
Hedge Funds Weigh In On Lipocine
A hedge fund recently raised its stake in Lipocine stock. Renaissance Technologies LLC grew its holdings in shares of Lipocine Inc. (NASDAQ:LPCN – Free Report) by 21.8% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 25,697 shares of the specialty pharmaceutical company’s stock after purchasing an additional 4,600 shares during the period. Renaissance Technologies LLC owned about 0.48% of Lipocine worth $212,000 as of its most recent SEC filing. Institutional investors own 9.11% of the company’s stock.
Lipocine Company Profile
Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.
Further Reading
- Five stocks we like better than Lipocine
- High Dividend REITs: Are They an Ideal Way to Diversify?
- How Whitestone REIT Is Transforming Sun Belt Retail Growth
- Canadian Penny Stocks: Can They Make You Rich?
- Top-Performing Non-Leveraged ETFs This Year
- 3 Small Caps With Big Return Potential
- Rivian’s Wild Ride: Is the Dip a Buying Opportunity?
Receive News & Ratings for Lipocine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine and related companies with MarketBeat.com's FREE daily email newsletter.
